Advancing Clinical Evidence in Infectious Diseases: An Infectious Diseases Clinical Trials Network for Asia, the "Antimicrobial Resistance Hot Zone".
other
Where this comes from
- Record sourced from PubMed, PMID 42227050.
- Also identified by DOI 10.1093/cid/ciag122.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
ADVANCE-ID (ADVancing Clinical Evidence in Infectious Diseases) is a clinical trials network comprising more than 100 hospitals across Asia, with additional research sites planned for Africa, the Middle East, and Latin America. The mission of ADVANCE-ID is to conduct high-quality clinical trials that have a global impact on the management of infection. More than 12 000 patients have been enrolled since 2022 in ADVANCE-ID studies. A key aim of ADVANCE-ID is to create evidence from randomized controlled trials to improve treatment, diagnostics, and prevention strategies of serious infections resulting from antimicrobial-resistant bacterial infections. Alongside this, ADVANCE-ID has a commitment to advocate for access to antibiotics and diagnostics for which evidence exists for their use in low- and middle-income countries.
Medical subject headings
- Communicable Diseases
- Anti-Bacterial Agents
- Drug Resistance, Bacterial
- Clinical Trials as Topic